Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 5556.00p Bid 5555.00p Ask 5556.00p Change -1.50%
Last Updated: 22/01/2019 21:46. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Financial Highlights Year Ended 31/12/2017

Turnover
£22,465.00m
Operating Profit
£3,677.00m
Dividend Yield
3.58
Dividend Per Share
202.50
Dividend Cover
1.17
P/E Ratio
23.80

Key Personnel

Pascal Claude Roland Soriot
Chief Executive Officer
Marc Pierre Jean Dunoyer
Chief Financial Officer
Leif Valdemar Johansson
Non-Executive Chairman
Tony Shu Kam Mok
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Rudolph Harold Peter Markham
Non-Executive Director
Prof Sabera Nazneen Rahman
Non-Executive Director
Sherilyn Dawn McCoy
Non-Executive Director
Deborah DiSanzo
Non-Executive Director
Graham Andrew Chipchase
Non-Executive Director
Philip Arthur John Broadley
Non-Executive Director
Prof Geneviève Bernadette Berger
Non-Executive Director

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,267,039,436
Market cap
£71,461.02m

Analyst Views (14)

Strong Buy
 
42.86%
Buy
 
7.14%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
5555.50p
Bid Price
5555.00p
Ask Price
5556.00p
Volume
1931509
Change Today
-84.50p
% Change Today
-1.50%
Open
5636.00p
Previous Close
5556.00p
Intraday High
5659.00p
Intraday Low
5533.00p
52 Week High
6432.00p
52 Week Low
4544.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

AstraZeneca Intra-day Chart

AstraZeneca News

News in this section is provided by MoneyAM

Broker Forecast - Societe Generale issues a broker note on AstraZeneca PLC 16 Jan 2019 | 11:30 AstraZeneca hires new oncology R&D head amid organisational revamp 07 Jan 2019 | 13:38 FTSE falls as UK growth forecasts lowered 20 Dec 2018 | 16:41 FTSE recovers some ground after early fall 20 Dec 2018 | 11:59 UK stocks fall after Wednesday's US rate hike 20 Dec 2018 | 09:32 AstraZeneca's chronic kidney disease treatment meets primary objectives 20 Dec 2018 | 07:34 AstraZeneca's ovarian cancer drug gets US regulatory nod after meeting primary objective 20 Dec 2018 | 07:19 AstraZeneca's partner FibroGen gets nod to market anaemia treatment in China 18 Dec 2018 | 09:54 Broker Forecast - Morgan Stanley issues a broker note on AstraZeneca PLC 14 Dec 2018 | 09:30 Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC 11 Dec 2018 | 08:30 Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC 10 Dec 2018 | 08:40 Surging oil prices boost FTSE 07 Dec 2018 | 16:48 Investors remain shaky after stock market volatility 07 Dec 2018 | 11:58 UK stocks bounce 1.6%, though investors remain on edge 07 Dec 2018 | 08:53 AstraZeneca's head and neck cancer treatment fails to meet primary goal 07 Dec 2018 | 07:42 Director Deals - AstraZeneca PLC (AZN) 04 Dec 2018 | 15:10 FTSE's trade-related boost loses some momentum 03 Dec 2018 | 16:38 Risk on sentiment helps lift FTSE and oil 03 Dec 2018 | 12:05 UK stocks open 2.2% higher as US, China declare trade war truce 03 Dec 2018 | 09:05 AstraZeneca agrees to offload rights for two drugs to Grunenthal for $815m 03 Dec 2018 | 07:20 Global equities surge on oil recovery 26 Nov 2018 | 17:00 Oil recovery and anticipated strength in US stocks continues to sustain FTSE 26 Nov 2018 | 11:59 AstraZeneca's rare autoimmune disease treatment receives orphan drug designation from FDA 26 Nov 2018 | 07:17 FTSE loses momentum amid renewed weakness in US markets 19 Nov 2018 | 16:36 Broker Forecast - Investec issues a broker note on AstraZeneca PLC 19 Nov 2018 | 11:00 Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC 19 Nov 2018 | 08:00 FTSE struggles against stronger pound 16 Nov 2018 | 16:48 Sterling recovery hits FTSE 100 16 Nov 2018 | 12:02 UK stocks open 0.5% higher as May's leadership hangs in the balance 16 Nov 2018 | 08:57 AstraZeneca cancer drug fails to meet primary objective 16 Nov 2018 | 07:22

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
7,615.0
6,848.0
Intangible Assets & Goodwill
38,013.0
39,244.0
Investments & Other Non-Current Assets
4,576.0
3,172.0
Total Non-Current Assets
50,204.0
49,264.0
Inventory
3,035.0
2,334.0
Trade & Receivables
5,009.0
4,573.0
Cash & Receivables
3,324.0
5,018.0
Other Current Assets & Assets Held for Resale
1,782.0
1,337.0
Total Assets
63,354.0
62,526.0

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
16,383.0
15,256.0
Long Term Liabilities
30,329.0
30,601.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
46,712.0
45,857.0

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
16,642.0
16,669.0

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
317.0
316.0
Minority Interests
1,682.0
1,815.0
Retained Earnings
8,221.0
8,140.0
Share Premium Account
4,393.0
4,351.0
Other Equity
2,029.0
2,047.0
Total Equity
16,642.0
16,669.0

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
3,578.0
4,145.0
Cashflow Before Financing
1,250.0
176.0
Increase / Decrease in Cash
-1,686.0
-1,148.0

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
22,465.0
23,002.0
Cost of Sales
4,318.0
4,126.0
Gross Profit
18,147.0
18,876.0
Operating Profit
3,677.0
4,902.0
Pre-Tax Profit
2,227.0
3,552.0
Profit / Loss for the Year
2,868.0
3,406.0

Dividend History

Data has been provided by MoneyAM

Period
Ex-Dividend Date
Payment Date
H1 Dividend
09 Aug 2018
10 Sep 2018
H2 Dividend
15 Feb 2018
19 Mar 2018
H1 Dividend
10 Aug 2017
11 Sep 2017
H2 Dividend
16 Feb 2017
20 Mar 2017
H1 Dividend
11 Aug 2016
12 Sep 2016
H2 Dividend
18 Feb 2016
21 Mar 2016
H1 Dividend
13 Aug 2015
14 Sep 2015
H2 Dividend
19 Feb 2015
23 Mar 2015
H1 Dividend
13 Aug 2014
15 Sep 2014
H2 Dividend
19 Feb 2014
24 Mar 2014
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.